Abstracts Archive - Page 737 of 2425 - ACR Meeting Abstracts

Abstract Number: 1235 • ACR Convergence 2020
Radiographic Progression of Structural Joint Damage over 5 Years of Baricitinib Treatment in Patients with Rheumatoid Arthritis: Results from RA-BEYOND
Désirée van der Heijde¹, Cynthia E Kartman², Li Xie², Scott Beattie², Douglas Schlichting², Patrick Durez³, Yoshiya Tanaka⁴ and Roy Fleischmann⁵, ¹Leiden University Medical Center, Leiden, Netherlands, ²Eli Lilly and Company, Indianapolis, IN, ³Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁵Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Baricitinib (BARI) is an oral, reversible and selective Janus kinase 1 and 2 inhibitor. Treatment with once-daily oral BARI resulted in low rates of…
Abstract Number: 1236 • ACR Convergence 2020
Association Between Change in Health Assessment Questionnaire Disability Index and Treatment Response in Patients with Rheumatoid Arthritis in Tocilizumab Clinical Trials
Sebastian Unizony¹, Joseph Dang², Jian Han³, Margaret Michalska² and Jennie H. Best², ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Genentech, Inc., South San Francisco, ³Genentech, South San Francisco, CA
Background/Purpose: The efficacy and safety of intravenous (IV) and subcutaneous (SC) tocilizumab (TCZ) in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and as monotherapy…
Abstract Number: 1237 • ACR Convergence 2020
Pain and Other Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response Based on Improvement in Swollen Joints in Tocilizumab Clinical Trials
Anthony Sebba¹, Jian Han² and Shalini V. Mohan², ¹Arthritis Associates, Palm Harbor, Tampa, FL, ²Genentech, South San Francisco, CA
Background/Purpose: Recent data suggest that rheumatoid arthritis (RA) pain may be noninflammatory and inflammatory, and improvement in pain scores and other patient-reported outcomes (PROs) may…
Abstract Number: 1238 • ACR Convergence 2020
Associations Between Rheumatoid Arthritis Disease Activity and Patient-reported Outcomes in Sarilumab Clinical Trials
Gerd Burmester¹, Laure Gossec², Hubert van Hoogstraten³, Amy Praestgaard⁴, Gregory St John⁵, Thomas Huizinga⁶, Daniel Aletaha⁷ and Roy Fleischmann⁸, ¹Charité University Hospital Berlin, Berlin, Germany, ²Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ³Sanofi, Bridgewater, NJ, ⁴Sanofi, Cambridge, MA, ⁵Regeneron Pharmaceuticals Inc, Tarrytown, NY, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria, ⁸Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Sarilumab is a human IL-6 receptor inhibitor approved for the treatment of adults with moderately to severely active RA. The relationship between disease activity,…
Abstract Number: 1239 • ACR Convergence 2020
Peripheral Protein Biomarker Changes Following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Methotrexate Naïve Adults with Moderately-to-Severely Active Rheumatoid Arthritis
Peter Taylor¹, Amer Mirza², Bryan Downie², Jinfeng Liu², Rachael Hawtin² and Emon Elboudwarej², ¹Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Gilead Sciences, Inc., Foster City
Background/Purpose: Filgotinib (FIL), an oral selective JAK1 inhibitor, has shown efficacy and safety in phase 3 studies in adults with moderately-to-severely active rheumatoid arthritis (RA),…
Abstract Number: 1240 • ACR Convergence 2020
An Increase in Red Cell Mean Corpuscular Volume by Methotrexate Is Potentiated by Hydroxychloroquine and Predicts Clinical Response in Rheumatoid Arthritis
Muhammad Shipa¹, Su-Ann Yeoh¹, Dev Mukerjee² and Michael Ehrenstein¹, ¹University College London, LONDON, United Kingdom, ²North Middlesex University hospital NHS Trust, London, United Kingdom
Background/Purpose: Methotrexate (MTX) can result in an increase in mean corpuscular volume (MCV) of red blood cells. The range of MCV change varies between patients…
Abstract Number: 1241 • ACR Convergence 2020
Patient-Reported Outcomes in Rheumatoid Arthritis Patients Treated with Tofacitinib or Biological DMARDs in Real Life Conditions in Two Latin America Countries
Hugo Madariaga¹, Juan Reyes², Magda Gutierrez³, Dario Ponce de Leon⁴, Tatjana Lukic⁵ and Luisa Amador², ¹Centro Medico CEEN, Arequipa, Arequipa, Peru, ²Pfizer, Bogota, Cundinamarca, Colombia, ³Pfizer, Santiago, Region Metropolitana, Chile, ⁴PFIZER, LIMA, Peru, ⁵Pfizer Inc, New York, NY
Background/Purpose: The objective of this study was to describe the efficacy, safety and patient reported outcomes in Latin-American patients with Rheumatoid Arthritis (RA) treated with…
Abstract Number: 1242 • ACR Convergence 2020
Transcranial Direct Current Stimulation for Fatigue in Patients with Sjogren’s Syndrome: A Randomized, Double-blind Pilot Study
Ana Pinto¹, Sara Piva², Alexia Vieira³, Samantha Gomes³, Aline Rocha⁴, Daniela Tavares³, Marcia Santana³, Cristiane Carlesso⁵, Adagmar Andriolo³, Fania Santos⁶, Felipe Fregni⁷ and Virginia Trevisani³, ¹Universidade Federal do Amapa, Sao Paulo, Brazil, ²Department of Physical Therapy, University of Pittsburgh, Pittsburgh, PA, ³Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ⁴Universidade Federal de Sao Paulo, Sao Paulo, Sao Paulo, Brazil, ⁵University of Pittsburgh, Pittsburgh, ⁶Universidade Federal de Sao Paulo, Sao Paulo, Saint Helena, ⁷Harvard Medical School, Cambridge, MA
Background/Purpose: Transcranial direct-current stimulation (tDCS) has shown promise to decrease fatigue. However, it has never been examined in primary Sjogren Syndrome (pSS). We aimed to assess…
Abstract Number: 1243 • ACR Convergence 2020
Self-reported Fatigue in Patients with Primary Sjögren’s Syndrome Is Associated with an Objective Decline in Physical Performance and Symptoms of Pain and Depression
Roeland Prak¹, Suzanne Arends², Greetje van Zuiden¹, Frans Kroese¹, Hendrika Bootsma¹ and Inge Zijdewind¹, ¹University Medical Centre Groningen, Groningen, Netherlands, ²University Medical Centre Groningen and Medical centre Leeuwarden, Groningen, Netherlands
Background/Purpose: Fatigue is a major complaint in autoimmune diseases including primary Sjögren’s syndrome (pSS). For many pSS patients, fatigue is their most dominant and disabling…
Abstract Number: 1244 • ACR Convergence 2020
Clinical Characteristics and Outcomes in Patients with Primary Sjögren’s Syndrome-Associated Interstitial Lung Disease
Joanna Marco¹, Gregory Gardner¹ and Nishant Gupta², ¹University of Washington, Seattle, WA, ²University of Cincinnati, Cincinnati
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a chronic autoimmune exocrinopathy that features interstitial lung disease (ILD) in up to 16% of patients. The clinical characteristics…
Abstract Number: 1245 • ACR Convergence 2020
Smoking Might Reduce Odds of Sjӧgren’s Syndrome Among Rheumatoid Arthritis Patients
Sara McCoy¹ and Christie Bartels², ¹University of Wisconsin, Madison, ²University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI
Background/Purpose: Smoking increases the risk of many rheumatic disease, including rheumatoid arthritis (RA). Previous studies have identified that current smoking might reduce the risk of…
Abstract Number: 1246 • ACR Convergence 2020
Sjogren’s Syndrome and Its Risk of Cervical Lesions
Kelly Corbitt¹, Isis Lopez² and Schartess Culpepper³, ¹Jackson Memorial Hospital/University of Miami Internal Medicine Residency Program, Miami, ²Baylor College of Medicine Rheumatology Fellowship Program, Miami, ³University of Miami Hospital System, Miami
Background/Purpose: Sjogren’s syndrome is chronic inflammatory disease that results in lacrimal and salivary dysfunction and can include extra-glandular manifestations. While it is well established that…
Abstract Number: 1247 • ACR Convergence 2020
Features of Childhood Sjogren’s Syndrome: A Literature Review Based Cohort
Achille Marino¹, Micol Romano², Teresa Giani³, Carla Gaggiano⁴, Stefania Costi⁵, Revika Singh⁶, Jay Mehta⁷, Scott Lieberman⁸ and Rolando Cimaz⁹, ¹Department of Pediatrics, Desio Hospital, Milan, ²ASST Gaetano Pini-CTO Institute, Milan, Italy, Milan, Italy, ³AOU Meyer, Florence, Italy, ⁴Department of Pediatrics, University of Siena, Siena, Italy, Siena, Italy, ⁵University of Milan, Milan, Italy, Milan, Italy, ⁶Northwestern University, Evanston, IL, ⁷Division of Rheumatology, Children's Hospital of Philadelphia, Philadelphia, USA, Philadelphia, PA, ⁸Department of Pediatrics, University of Iowa, Iowa City, US, Iowa City, IA, ⁹ASST Gaetano Pini-CTO Institute and Università degli Studi di Milano, Milan, Italy, Milan, Italy
Background/Purpose: Sjogren’s syndrome (SS) is an autoimmune chronic disease characterized by inflammation of exocrine glands, but it can affect other organs as well.This study aims…
Abstract Number: 1248 • ACR Convergence 2020
Patients Seropositive for La/SSB Without Ro/SSA Differ from Those Displaying La/SSB with Ro/SSA in a Single Center Sjogren’s Cohort
Rana Mongroo¹, Samira Chowdhury² and Steven Carsons², ¹Mount Sinai South Nassau Hospital, Mineola, NY, ²NYU Winthrop Hospital, Mineola, NY
Background/Purpose: Sjögren’s disease (SS) is characterized by the presence of antibodies against protein-small RNP complexes designated Ro/SSA and La/SSB. Both are included in the 2002…
Abstract Number: 1249 • ACR Convergence 2020
The Impact of Anti-Ro Antibodies on the Pregnancy Outcome in Relation to Maternal Disease Presentation: A Descriptive Analysis of 231 Pregnancies
Eman Satti¹, Nawal Hadwan¹, Hadil Ashour¹, Rawan Saleh¹, Fiaz Alam¹, Omar Alsaed¹ and Samar Al Emadi¹, ¹Hamad medical corporation, DOHA, Qatar
Background/Purpose: Anti-Ro antibody positivity is linked to adverse fetal outcomes like congenital heart block CHB (2%) and neonatal lupus. The incidence of CHB increases to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].